| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
TÜBINGEN, Germany—Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced in July that it had entered into a research collaboration and license agreement with Genmab A/S to develop next-generation, T cell-engaging, bispecific immunotherapies targeting multiple cancer indications.
 
The companies will conduct joint research, funded by Genmab, to combine Immatics’ XPRESIDENT and Bispecific TCR technology platforms with Genmab’s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology. The companies will exclusively discover and develop immunotherapies directed against three proprietary targets, which were discovered and developed by Immatics’ XPRESIDENT technology. Genmab has the option to exclusively license up to two additional targets to expand the partnership at predetermined economics.
 
Genmab will be responsible for development, manufacturing and worldwide commercialization. Immatics will have an option to contribute certain promotion efforts at predetermined levels in selected countries in the European Union.
 
Under the terms of the agreement, Immatics will receive an upfront fee of $54 million and is eligible to receive up to $550 million in development, regulatory and commercial milestone payments for each product and tiered royalties up to a double-digit percentage of net sales.
 
“This collaboration underpins Immatics’ leadership in intracellular tumor target identification and T cell receptor engineering,” said Dr. Carsten Reinhardt, chief medical officer and managing director of Immatics. “Our bispecific TCR technology exhibits exceptional potency and favorable pharmacokinetic properties by combining Immatics’ proprietary T cell-engaging format with our high-affinity and highly specific T cell receptors, as reported at AACR 2018.”
 
“This collaboration with Immatics gives us the opportunity to combine our unique technologies and expertise to create differentiated novel next-generation therapies. We very much look forward to this exciting partnership in the field of cancer immunotherapy,” added Dr. Jan van de Winkel, CEO of Genmab.

Related Topics

Published In

Volume 14 - Issue 9 | September 2018

September 2018

September 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue